Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Alves, Iane Pinto Figueiredo Lima, Brett G M Hughes, Yoann Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin Hetnał, Jean-Pierre Delord, Ricard Mesía, Miren Taberna, John N Waldron, Christian Simon, Vincent Grégoire, Kevin J Harrington, Ramona F Swaby, Yayan Zhang, Burak Gumuscu, Behzad Bidadi, Lillian L Siu
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC. METHODS: In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally were randomly assigned (1:1) to pembrolizumab (200 mg) plus chemoradiotherapy or placebo plus chemoradiotherapy...
March 29, 2024: Lancet Oncology